Status:
COMPLETED
Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease Patients
Lead Sponsor:
Ricardo Mouzo Mirco
Conditions:
Chronic Kidney Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Use of Paricalcitol in stage Vd Chronic Kidney Disease patients, over the effect of inflammatory and oxidative stress parameters.
Detailed Description
Use of Paricalcitol in stage Vd Chronic Kidney Disease patients using a permanent catheter due to haemodialysis; over the effect of inflammatory and oxidative stress parameters. This study uses parica...
Eligibility Criteria
Inclusion
- Vd CKD patients using haemodialysis during 3 or more months.
- Tunnelized-bearer permanent catheters on haemodialysis at last 6 months previous at the beginning of the study. .
- Kt stable, over 45 litres on both sexs.
- Patients in treatment wiht atorvastatin
- Patients without infectious or inflammatory processes over 8 weeks.
- Two consecutive PTH \< than 400 pg/ml; Ca\<10.2 and P \<7.0 mg/dl.
Exclusion
- Patients \> 18 years.
- Pregnant women.
- Patients hospitalized 4 weeks before the beginning of the treatment.
- Immunosuppressor intake.
Key Trial Info
Start Date :
August 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2014
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT01820767
Start Date
August 1 2012
End Date
March 1 2014
Last Update
August 24 2018
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital El Bierzo. Servicio de Nefrología.
Ponferrada, (León)., Spain, 24411,
2
Hospital de León
León, Spain, 24008